Takakusagi Yosuke, Suga Makito, Kusano Yohsuke, Kano Kio, Shima Satoshi, Tsuchida Keisuke, Mizoguchi Nobutaka, Serizawa Itsuko, Yoshida Daisaku, Kamada Tadashi, Minohara Shinichi, Katoh Hiroyuki
Department of Radiation Oncology, Kanagawa Cancer Center, Yokohama, JPN.
Division of Radiation Therapy Technology, Kanagawa Cancer Center, Yokohama, JPN.
Cureus. 2022 Feb 14;14(2):e22214. doi: 10.7759/cureus.22214. eCollection 2022 Feb.
Background/Aim The efficacy and safety of carbon-ion radiotherapy (CIRT) for prostate cancer have already been demonstrated. The number of hemodialysis (HD) patients is increasing. Although the toxicity of CIRT in HD patients may be more severe, it has been insufficiently investigated. Therefore, we retrospectively analyzed the safety of CIRT for HD patients with prostate cancer in the present study. Materials and methods Five HD patients with prostate cancer who underwent CIRT at the Kanagawa Cancer Center during November 2015-2020 were included in this study. CIRT was delivered by the raster scanning method (sCIRT). Adverse events were assessed using the Common Terminology Criteria for Adverse Events version 5.0. The dose-volume histogram (DVH) parameters of the target volume and normal organs were evaluated between initial planning computed tomography (CT) and in-room CT images. Results In the acute phase, Grade 1 genitourinary toxicity was recorded in one patient. In the late phase, Grade 1 genitourinary toxicity was recorded in two patients. No gastrointestinal toxicities were noted during the follow-up period. In-room CT analysis revealed no significant differences among all DVH parameters of the target volume and normal organs when compared with the treatment plan dose. Conclusions The safety of sCIRT for prostate cancer in HD patients was investigated in the present study. In-room CT analysis suggested the robustness of the treatment plan. According to the present results, sCIRT for prostate cancer can be safely performed in HD patients.
背景/目的 碳离子放疗（CIRT）治疗前列腺癌的有效性和安全性已得到证实。血液透析（HD）患者的数量正在增加。尽管CIRT对HD患者的毒性可能更严重，但对此研究不足。因此，我们在本研究中回顾性分析了CIRT治疗HD前列腺癌患者的安全性。材料与方法 本研究纳入了2015年11月至2020年期间在神奈川癌症中心接受CIRT的5例HD前列腺癌患者。CIRT采用光栅扫描法（sCIRT）进行。使用不良事件通用术语标准第5.0版评估不良事件。在初始计划计算机断层扫描（CT）和术中CT图像之间评估靶区体积和正常器官的剂量体积直方图（DVH）参数。结果 在急性期，1例患者记录为1级泌尿生殖系统毒性。在后期，2例患者记录为1级泌尿生殖系统毒性。随访期间未发现胃肠道毒性。术中CT分析显示，与治疗计划剂量相比，靶区体积和正常器官的所有DVH参数之间无显著差异。结论 本研究调查了sCIRT治疗HD前列腺癌患者的安全性。术中CT分析表明治疗计划具有稳健性。根据目前的结果，HD患者可以安全地进行sCIRT治疗前列腺癌。
